Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
Portfolio Pulse from
Theravance Biopharma, Inc. reported record financial results for Q4 and FY 2024, with YUPELRI net sales reaching $66.7 million in Q4 and $238.6 million for the year. TRELEGY net sales, reported by GSK, were $3.46 billion, triggering a $50 million milestone payment to Theravance. The company ended Q4 with $88 million in cash, excluding the milestone payment.
February 26, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theravance Biopharma reported record financial results for Q4 and FY 2024, with significant sales growth in YUPELRI and a $50 million milestone from TRELEGY sales.
The record sales figures for YUPELRI and the milestone payment from TRELEGY indicate strong financial performance, likely boosting investor confidence and positively impacting the stock price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100